Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Dianthus Therapeutics’ FY2024 earnings at ($2.54) EPS.

A number of other equities analysts have also recently commented on DNTH. Lifesci Capital raised shares of Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Raymond James boosted their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an outperform rating in a report on Thursday, April 18th. HC Wainwright initiated coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They set a buy rating and a $40.00 price target for the company. Wedbush increased their price objective on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an outperform rating in a research report on Friday, May 10th. Finally, Jefferies Financial Group raised their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a buy rating in a research report on Friday, March 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of Buy and an average price target of $42.83.

Dianthus Therapeutics Trading Up 3.9 %

Shares of DNTH opened at $25.88 on Thursday. The company’s fifty day simple moving average is $23.77 and its 200 day simple moving average is $21.65. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The company has a market cap of $759.58 million, a price-to-earnings ratio of -4.44 and a beta of 1.83.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The company had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.48 million. As a group, research analysts forecast that Dianthus Therapeutics will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after purchasing an additional 74,000 shares in the last quarter. Vestal Point Capital LP acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $1,404,000. FMR LLC bought a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $28,961,000. Citigroup Inc. bought a new position in shares of Dianthus Therapeutics during the third quarter valued at $53,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Dianthus Therapeutics during the third quarter worth $303,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.